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Abstract
Background
Persons living with HIV on combination antiretroviral therapy (cART) may be at increased
risk of the development of age-associated non-communicable comorbidities (AANCC) at
relatively young age. It has therefore been hypothesised that such individuals, despite effec-
tive cART, may be prone to accelerated aging.
Objective
The COmorBidity in Relation to AIDS (COBRA) cohort study was designed to investigate
the potential causal link between HIV and AANCC, amongst others, in a cohort of middle-
aged individuals with HIV with sustained viral suppression on cART and otherwise compara-
ble HIV-negative controls.
Methods
Longitudinal cohort study of HIV-positive subjects45 years of age, with sustained HIV sup-
pression on cART recruited from two large European HIV treatment centres and similarly-
aged HIV-negative controls recruited from sexual health centres and targeted community
groups. Both HIV-positive and HIV-negative subjects were assessed at study entry and
again at follow-up after 2 years.
Results
Of the 134 HIV-positive individuals with a median (IQR) age of 56 (51, 62) years recruited,
93% were male, 88% of white ethnicity and 86% were men who have sex with men (MSM).
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Similarly, the 79 HIV-negative subjects had a median (IQR) age of 57 (52, 64) and 92%
were male, 97% of white ethnicity and 80% were MSM.
Conclusions
The results from the COBRA study will be a significant resource to understand the link
between HIV and AANCC and the pathogenic mechanisms underlying this link. COBRA will
inform future development of novel prognostic tools for earlier diagnosis of AANCC and of
novel interventions which, as an adjunct to cART, may prevent AANCC.
Introduction
Combination antiretroviral therapy (cART) has reduced the risk of AIDS-defining illnesses
and their associated mortality, and has markedly and sustainably improved survival for people
living with HIV [1, 2]. As a consequence of the rising average age of those living with HIV,
morbidity and mortality in these individuals is increasingly a result of age-associated non-
communicable co-morbidities (AANCC) such as cardiovascular disease, diabetes mellitus,
chronic kidney and liver disease, osteoporosis, non-AIDS associated malignancies, chronic
obstructive pulmonary disease, as well as cognitive impairment [3–5].
As treated HIV-positive individuals age, their care becomes increasingly complex and chal-
lenging because of the need to prevent and manage multiple concomitant AANCC. The result-
ing requirement for integrated multidisciplinary care (including disciplines not traditionally
heavily involved in the management of HIV-positive patients) will present new challenges for
health-care providers [6] [7] [8].
Moreover, AANCC, and possibly their treatment, may undermine sustained adherence to
lifelong cART with the resulting polypharmacy leading to an increased potential for drug-drug
interactions, thereby potentially jeopardizing both the long-term effectiveness of cART for the
individual, as well as its benefits to society in preventing onward HIV transmission [9].
Recent studies have suggested that in people living with HIV several AANCC may occur
more frequently and at an earlier age than in HIV-negative individuals [10–12]. Whilst these
findings should be interpreted with caution, these observations may partly explain the finding
that, despite the use of cART, the estimated average life expectancy of people living with HIV
remains shorter than that of HIV-negative persons of the same age, particularly when diagno-
sis and treatment of HIV infection is delayed to an advanced disease stage (i.e., AIDS and/or
severe immunodeficiency with CD4+ T-cell counts below 200 cells/μL) [13, 14]. As a conse-
quence, there continues to be a reduced probability that people living with HIV will experience
healthy aging with good quality of life while remaining able to work and contribute economi-
cally and in other ways to society.
In studies conducted thus far, early onset and occurrence of AANCC were common in
HIV-positive people with traditional modifiable or unmodifiable demographic, lifestyle-
related and behavioural risk factors for AANCC. Among these AANCC, clinically significant
cognitive impairment is often observed in people living with HIV on cART [15, 16]. Neuro-
imaging is beginning to provide important insights into the pathogenesis of HIV-associated
cognitive impairment [17, 18] and recent advances in magnetic resonance imaging (MRI)
allow further study of brain structure and function in greater detail and thus increase our
understanding of the pathogenesis of HIV-associated cognitive impairment.
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Other factors related to HIV, including activation of the innate and adaptive immune sys-
tem, immune exhaustion and senescence and chronic inflammation, likely causally contribute
to the increased and premature risk of AANCC [19]. These immune pathologies may lead to a
process of accentuated and/or accelerated aging, given that they are features of chronic HIV
infection and have each also been associated with aging [20]. A number of biomarkers, indica-
tive of persistent immune activation, inflammation, coagulation activation, and neuronal dam-
age, have been studied in HIV-positive subjects, and a strong association has been
documented between some of these biomarkers and all-cause mortality [21, 22]. However,
their relation to the development of specific comorbidities has not been as extensively studied.
HIV infection and the presence/absence of cART may affect the complex interplay between
the innate and adaptive immune system, inflammation, the central and autonomic nervous
system. These interrelated mechanisms are thought to jointly enhance the pathogenesis of
AANCC (including cognitive impairment), and thereby may explain the increased risk and
possible premature onset of these conditions in persons living with HIV on cART. Novel
promising candidate biomarkers of aging have recently been identified [23], but have not yet
been validated in the setting of HIV infection. The simultaneous analysis of both these novel
aging biomarkers as well as those of altered metabolism, residual HIV replication and produc-
tion, immune activation and senescence, inflammation, coagulation activation, antiretroviral
pharmacology, and neuronal damage is therefore important to clarify the potential pathogenic
mechanisms underlying the links between HIV and AANCC.
In this context, the COmorBidity in Relation to AIDS (COBRA) cohort study was designed
to investigate the potential causal link between HIV and AANCC, amongst others, in a cohort
of middle-aged individuals with HIV on suppressive cART and otherwise comparable HIV-
negative controls. The objectives of the COBRA study are:
i. to investigate the association between HIV infection and AANCC (including cognitive
function);
ii. to further elucidate possible causative links between HIV and AANCC;
iii. to clarify the potential pathogenic mechanisms underlying any links identified, including
the possible induction of an inflammation-associated accelerated aging phenotype;
iv. to identify biomarkers (or combinations of biomarkers) that may be used for better pre-
vention, treatment and management of AANCC.
Cohort studies like COBRA, can only establish associations. In order to fulfil objective ii. a
“Human Immune System” mouse model has been developed allowing to distinguish the effect
of exposure to HIV and cART on various metabolic outcomes as well as immune and aging
biomarkers, when applied under controlled conditions. The methods and results of this mouse
model are beyond the scope of this paper and will be reported elsewhere.
The COBRA study was funded through the European Union Seventh Framework Pro-
gramme in 2013 following independent peer review of the planned study design. The current
paper sets out the key aspects underlying the COBRA cohort study, including its design, meth-
ods, demographic characteristics of the participants at study entry and their overall representa-
tiveness of the two larger European aging cohorts of people living with HIV.
Methods
Study design
The COBRA clinical cohort is a longitudinal cohort study of middle-aged HIV-positive sub-
jects with sustained HIV suppression on cART recruited from two large European HIV
The COBRA cohort
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treatment centres and similarly-aged HIV-negative controls recruited from sexual health cen-
tres and targeted community groups. Both HIV-positive and HIV-negative subjects underwent
a first study visit at study entry with a comprehensive assessment for AANCC, cognitive test-
ing, biomarker measurements and MRI scanning. All subjects underwent a repeat assessment
at approximately two years later; a two-year follow up period was considered sufficient to
detect meaningful changes in biomarkers and neuroimaging outcomes based on previously
reported results.
At baseline, details captured included participant demographics, socioeconomic status,
detailed medical history including details of lifestyle, use of (non-antiretroviral) medication,
anthropometric assessments, questionnaires on quality of life, work participation and depres-
sion, detailed cognitive function assessment, respiratory function (spirometry), cardiovascular
function assessment (ECG and arterial stiffness assessment), spine, hip and femoral neck dual
energy X-ray absorptiometry (DXA) scan for bone mineral density, assessment of falls risk
and fracture risk and frailty assessment.
Different types of biological material were sampled at both baseline and follow up visit for
biomarker analysis (blood cells and serum/plasma, peripheral blood mononuclear cells
(PBMC), DNA, cerebrospinal fluid (CSF), urine and stool). Different sets of biomarkers were
measured, including markers of residual HIV replication and production, immune activation
and senescence, inflammation, coagulation activation, antiretroviral pharmacokinetics, neuro-
nal damage and ageing (glycan profiles, genetic, epigenetic, mRNA and microRNA ratio
sequencing). Complete details, including sampling methods and procedures, are reported in
the supplementary material (S1 File) and, for some sets of biomarkers in Booiman T. et al [24]
and Booiman T. et al [25].
Detailed cognitive function assessment was carried out at both baseline and follow up and
included all major cognitive domains: attention and working memory, speed of information
processing, memory and learning, language, executive function and psychomotor perfor-
mance (see S1 Table). In addition, acquired impairment of everyday functioning was assessed
by self-report questionnaires of cognitively related aspects, activities of daily living (Lawton
Instrumental Activities of Daily Living Scale) and depressive symptoms (Beck’s Depression
Inventory). These tests were selected to accurately assess cognitive function based on the cur-
rent literature, with the total testing time estimated to be approximately 120 minutes per sub-
ject, including resting time between tests. Designated trained clinical research staff undertook
the assessment of cognitive function at each clinical site, adhering to the study operations man-
ual for completing this battery in the same fashion in each study participant.
Historical information on HIV treatment, CD4+ T cell count and HIV viral load were
obtained for all HIV-positive subjects from national (Dutch and UK) HIV databases (https://
www.hiv-monitoring.nl/english/ and http://www.ctu.mrc.ac.uk/UKCHIC/indexUKCHIC.
asp).
In addition, multiple MRI modalities were used to acquire a wide range of complementary
measures of brain structure and function of all subjects at both baseline and follow up. Details
concerning the modalities and the data acquisition methods are reported in the supplementary
material (S2 File) and have been previously reported in Cole J. et al [26], Underwood J. et al
[27] and van Zoest R. et al [28].
A detailed data exchange platform was established prior to recruitment. This included
information on the standardisation of data across the two clinical cohorts (i.e. variable names,
formats, ranges of values and units of measurements), data quality assurance checks, data pro-
tection, data preservation and sharing. All data were transferred electronically from the clinics
and laboratories to the data co-ordinating centre in London.
The COBRA cohort
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Population
COBRA was conducted among individuals recruited at two clinical sites, in Amsterdam (Neth-
erlands) and London (UK) in order to obtain a sample representative of the aging HIV popula-
tion in Western and Northern Europe and to secure an adequate sample size. Participants
were recruited from ongoing prospective cohort studies on co-morbidity and aging in HIV
(the AGEhIV Cohort Study in Amsterdam [12] and the POPPY study in London [29]). Both
studies were set up with the objective of investigating the effects of ageing and comorbidities
in people living with HIV and recruited middle-aged HIV-positive subjects and HIV-negative
controls with similar demographics and lifestyles. Both studies adopted enrolment criteria for
HIV-positive participants to ensure these were representative of the population of people liv-
ing with HIV commonly seen in clinics in Amsterdam and in London. In order to best take
into account the effects of age, sex, other demographics as well as behavioural factors (includ-
ing sexual risk-taking behaviours) HIV-negative individuals were recruited into the two stud-
ies from sexual health clinics and targeted community groups. Moreover age, sex, and
ethnicity were regularly monitored, and enrolment was adjusted accordingly to ensure compa-
rability of HIV-positive and HIV-negative participants.
While these two studies comprehensively assessed a wide range of AANCC and associated
outcomes, patients enrolled within COBRA underwent further detailed assessments and test-
ing (cognitive testing, biomarker measurements and MRI scanning) as described in the previ-
ous section.
All COBRA participants were required to be aged 45 years or over and to be able to compre-
hend the study information leaflet. HIV-positive subjects were required to have a documented
HIV infection, to be on cART and to have had undetectable plasma HIV RNA (<50 copies/
mL) for12 months prior to enrolment. A confirmed negative HIV test was required for
HIV-negative subjects. Exclusion criteria were as follows: current major depression (as indi-
cated by a PHQ-9 questionnaire score15 at screening), confounding neurological diseases,
previous severe head injury (with loss of consciousness30 minutes), a history of cerebral
infections (including AIDS-defining diseases involving the central nervous system), current
intravenous drug use (in the past six months, based on self-report), daily use of recreational
drugs (with the exception of cannabis), excess alcohol intake (>48 units per week), severe psy-
chiatric disease or contraindication to MRI or lumbar puncture.
Sample size
The study was not designed to be powered to detect associations with clinical AANCC. Such a
study would be infeasible within most standard funding schemes given the high costs and
complexity of capturing the detailed neuro-imaging and biomarker (including cerebrospinal
fluid markers) data that were required. Rather, the target sample size was pragmatically set at
150 HIV-positive subjects (75 at each site) and 100 HIV-negative controls (50 at each site).
These numbers and the HIV-positive to HIV-negative ratio were considered, at the time, to be
feasible based on the size and design of the two ongoing larger cohort studies on co-morbidity
and aging in HIV in the Netherlands and in the UK, and based on the demand of time and
commitment from study participants required to complete all the planned assessments and
tests. Several members of the HIV community (as part of a wider scientific advisory board
nominated by the COBRA steering committee) were also involved in discussions around study
design, to ensure that recruitment methods and procedures would be acceptable to partici-
pants. Whilst no formal sample size calculation was performed (there was no primary end-
point and the distribution of many of the proposed biomarker outcomes in the HIV-positive
population had not been previously documented), it was recognised that a cohort of this size
The COBRA cohort
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would be substantially larger that most ongoing neuroimaging studies. In addition, given the
continuous nature of many of the biomarker and neuroimaging outcomes, this sample size
was believed to be sufficient to allow estimation of key parameters with sufficient precision to
allow meaningful comparisons of most outcomes, based on previously reported results from
similar studies.
Recruitment
Recruitment to the study took place between January 2013 and October 2014 with some partic-
ipants already enrolled in the AGEhIV study, who had been enrolled between December 2011
and December 2012, were also retrospectively recruited into the COBRA cohort. A follow-up
visit was planned for all recruited participants at approximately two years from the baseline
visit. Due to the difficulties of recruiting participants in one of the two sites, the Programme
Steering Committee made the decision to stop recruitment at the end of October 2014 in
order to ensure a comparable follow-up time of approximately two years for all participants.
When recruitment was stopped, 134 HIV-positive and 79 HIV-negative individuals had been
recruited. Whilst short of the original targeted sample size, these numbers were still considered
sufficient to achieve the cohort objectives. Follow-up visits took place approximately two years
after the first visit and were completed in June 2016.
Funding, consent and ethical approval
This study was supported by a European Union Seventh Framework Programme grant to the
Comorbidity in Relation to AIDS (COBRA) project (FP-7-HEALTH 305522, all authors),
National Institute for Health Research (NIHR) Professorship (NIHR-RP-011-048), NIHR
Imperial Biomedical Research Centre, the Netherlands Organisation for Health Research and
Development (grant number 300020007) & Stichting AIDS Fonds (grant number 2009063),
Nuts-Ohra Foundation (grant number 1003–026) and unrestricted scientific grants from: Gil-
ead Sciences, ViiV Healthcare, Janssen Pharmaceutica N.V. Bristol-Myers Squibb (BMS), and
Merck & Co to the AGEhIV cohort study, as well as investigator initiated grants from BMS,
Gilead Sciences, Janssen, Merck and ViiV Healthcare to the POPPY cohort study. The funders
had no role in study design, data collection and analysis, decision to publish, or preparation of
the manuscript.
This study was approved by the institutional review board of the Academic Medical Center
(AMC) (reference number NL 30802.018.09) and a UK Research Ethics Committee (REC)
(reference number 13/LO/0584 Stanmore, London). All participants gave written informed
consent.
Definitions of AANCC
In addition to the consideration of changes in the distribution of most markers of AANCC
(e.g. renal, liver and lipid profiles, glucose and haemoglobin A1c, thyroid, respiratory and car-
diovascular function assessment, and bone mineral density) several clinical definitions of
AANCC were pre-defined. Diabetes mellitus was considered to be present where at least one of
the following was present: self-report history of diabetes mellitus, use of blood glucose lower-
ing medication, fasting blood glucose7 mmol/L or non-fasting blood glucose11.1 mmol/
L, HbA1c48 mmol/mol. Hypertension was defined as use of antihypertensive drugs, all avail-
able systolic blood pressure measurements140 mmHg, and/or all available diastolic blood
pressure measurements90 mmHg. Dyslipidaemia was defined on the basis of the European
guidelines on cardiovascular disease prevention in clinical practice [30] as total cholesterol >5
mmol/L or low-density lipoprotein >3 mmol/L (in individuals with history of myocardial
The COBRA cohort
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infarction, heart failure, angina pectoris, narrowed blood vessels, stroke or diabetes mellitus
thresholds of<4.5 mmol/L and 2.5 mmol/L were applied). Micro-albuminuria was defined as
a urine albumin to creatinine ratio2.5 mg/mmol in males and3.5 mg/mmol in females;
proteinuria as a urine protein to creatinine ratio >15 mg/mmol. The glomerular filtration rate
(eGFR) was estimated using the Chronic Kidney Disease Epidemiology Collaboration
(CKD-EPI) formula [31]. Presence of osteopenia or osteoporosis of spine, hip and femoral neck
was defined as a DXA bone density -2.5 T-score−1, and T-score< -2.5, respectively. Mea-
sures of frailty were obtained from the walking speed (i.e. time taken to walk 15 feet) and the
hand grip strength test.
Statistical analyses
For the purpose of this report, comparison of participant characteristics at baseline among
HIV-positive and HIV-negative subjects was performed using Chi-squared test, Fisher’s exact
test or Wilcoxon rank-sum test, as appropriate. The distribution of socio-demographic and
life-style characteristics of participants enrolled in Amsterdam and in London was compared
to that of the AGEhIV and the POPPY cohorts, respectively, to ensure representativeness of
the COBRA cohort to the two larger HIV aging cohorts. Comparison was carried out using
Chi-squared test, Fisher’s exact test or Wilcoxon rank-sum test, as appropriate.
All the analyses were performed using SAS version 9.4 (SAS institute, Cary, NC, Murica)
and two-sided p-values<0.05 were considered as statistically significant.
Results
Participant characteristics
In total, 134 HIV-positive and 79 HIV-negative individuals over 45 years of age were enrolled
in the study as detailed in Fig 1. Socio-demographic, anthropometrics and life-style characteris-
tics at baseline in the two study groups are reported in Table 1. Participants were predominantly
Fig 1. Flowchart of COBRA study participants.
https://doi.org/10.1371/journal.pone.0191791.g001
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male (93.0%), men who have sex with men (MSM, 77.3%) and of white ethnicity (91.5%), with
a median (IQR: interquartile range) age of 56 years (51, 63). Groups were highly comparable in
terms of age, gender, sexual orientation, year of education, anthropometric characteristics,
smoking and use of injected and recreational drugs. HIV-positive participants were less likely to
be of white ethnicity (88.0% vs. 97.4%, p = 0.02), current drinkers (77.6% vs. 91.0%, p = 0.03)
and reported less years of alcohol consumption (p< 0.01) compared to HIV-negative controls.
HIV-positives had been diagnosed with HIV for a median (IQR) of 15.0 (9.1, 20.0) years previ-
ously, had been on cART for a median of 12.6 (7.4–16.9) years, all had an undetectable viral
load at baseline visit with a median (IQR) CD4+ cell count of 629 (472–806) cells/μL (Table 2).
A total of 11 HIV-positive participants (3 deaths and 8 withdrawals) and 1 HIV-negative
control did not take part in the follow up visit (Fig 1). These were all men, MSM, 91.7% were
of white ethnicity and with a median (IQR) age of 60 (51, 63) years; there were no significant
Table 1. Sociodemographic, anthropometric and lifestyle characteristics of study participants at first study visit.
Variable, n (%) or median (IQR) HIV-ve (N = 79) HIV+ve (N = 134) p-value
Study site 0.37
Netherlands 50 (63.3%) 75 (56.0%)
UK 29 (36.7%) 59 (44.0%)
Gender 0.79
Female 6 (7.6%) 9 (6.7%)
Male 73 (92.4%) 125 (93.3%)
Ethnicity 0.02
Black-African 2 (2.6%) 16 (12.0%)
White 76 (97.4%) 117 (88.0%)
Sexual orientation 0.45
Gay/homosexual 59 (74.7%) 104 (77.6%)
Bisexual 4 (5.1%) 10 (7.5%)
Heterosexual 16 (20.2%) 18 (13.4%)
Age in years 57 (52, 64) 56 (51, 62) 0.26
Years of education 16 (14, 17) 14 (13, 16) 0.23
Weight [kg] 81.2 (72.5, 91.0) 79.6 (70.0, 87.5) 0.13
Height [cm] 179 (173, 184) 178 (173, 182) 0.28
BMI [kg/m2] 24.6 (23.2, 28.4) 24.6 (22.6, 27.4) 0.30
Waist [cm] 93 (87, 104) 93 (88, 101) 0.98
Smoking status 0.26
Current smoker 20 (25.3%) 40 (29.9%)
Ex-smoker 29 (36.7%) 58 (43.3%)
Never smoked 30 (37.8%) 36 (26.9%)
Pack-years of smoking [current smokers] 8 (2, 42) 20 (8, 36) 0.20
Years of smoking [current/ex-smokers] 26 (15, 39) 29 (20, 37) 0.38
Alcohol consumption 0.03
Current drinker 71 (91.0%) 104 (77.6%)
Ex-drinker 3 (3.9%) 18 (13.4%)
Never drank 4 (5.1%) 12 (9.0%)
Years of drinking [current/ex drinkers] 41 (35, 47) 37 (31, 43) <0.01
Alcohol units/week [current drinkers] 7.5 (1.5, 17.5) 5.5 (1.5, 15.0) 0.37
Ever used injected drugs 0 (0.0%) 6 (4.5%) 0.09
Use of recreational drugs in past 6 months 18 (22.8%) 44 (32.8%) 0.16
https://doi.org/10.1371/journal.pone.0191791.t001
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differences in terms of gender, sexual orientation, ethnicity and age with participants who
completed follow up visit (all p-values were>0.1).
Representativeness of the Dutch and UK HIV aging cohorts
Table 3 and Table 4 report the comparison of study participants recruited in Amsterdam
(Netherlands) and London (UK) with participants of the two larger HIV cohort studies on
aging, the AGEhIV Cohort Study in Amsterdam [12] and the POPPY study in London [24],
respectively. In the Netherlands, both HIV-positive and HIV-negative COBRA participants
seem to be representative of the respective AGEhIV groups in terms of ethnicity, sexual orien-
tation, anthropometric and most lifestyle factors. No females were recruited in the COBRA
study, while these were approximately 13.8% and 16.6% of the remaining AGEhIV HIV-posi-
tive and HIV-negative participants, respectively (both p-values were <0.01). Compared to the
remaining AGEhIV participants, both COBRA groups were older, but only significantly so
were the HIV-negative participants (p<0.01).
COBRA participants recruited in the UK were well representative of the larger POPPY
cohort in terms of socio-demographic, anthropometric and lifestyle characteristics, with the
only exception of HIV-negative controls in COBRA being more likely to be current smokers
(44.8% vs. 11.7%) and reporting significantly more years of smoking [median (IQR) was 37
(27, 45) years vs. 25 (12, 36)] than the POPPY HIV-negative participants.
With regards to HIV-specific characteristics, HIV-positive participants recruited in the
Netherlands were more likely to have acquired HIV through homosexual sex (p<0.01) and,
due to study entry criteria, being on cART (p = 0.03) and virally suppressed (p<0.01), as
reported in Table 5. COBRA participants in the Netherlands were also known to be infected
for a longer time and reported a higher CD4+ T cell count. No significant differences were
found between HIV-positive individuals recruited in the UK and the remaining HIV-positive
POPPY participants.
Discussion
The COBRA study recruited 134 successfully treated HIV-positive individuals over 45 years of
age and 79 similarly aged, appropriately chosen and comparable HIV-negative controls. As
shown, HIV-positive and HIV-negative individuals are highly comparable with regards to
Table 2. HIV-specific characteristics of HIV-positive participants.
Variable, n (%) or median (IQR) HIV+ve (N = 134)
Likely route of HIV transmission
Men who have sex with men 115 (85.8%)
Heterosexual sex 15 (11.2%)
IVDU/Blood product 1 (0.8%)
Unknown 3 (2.2%)
Years since HIV diagnosis 15.0 (9.1, 20.0)
Currently on cART 134 (100%)
Duration of cART [years] 12.6 (7.4, 16.9)
HIV RNA viral load < 200 copies/mL 134 (100%)
Prior AIDS event 42 (31.3%)
CD4+ cell count [cells/μL] 629 (472, 806)
Nadir CD4+ cell count [cells/μL] 180 (90, 250)
CD4+:CD8+ cell count ratio 0.84 (0.60–1.12)
https://doi.org/10.1371/journal.pone.0191791.t002
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most sociodemographic, anthropometric and lifestyle characteristics. An appropriate control
group, as the one recruited within COBRA, is key in determining the effects of HIV and/or
HIV therapies on AANCC over and above those of lifestyle, ethnicity, socioeconomic, and
other modifiable behavioural factors.
Participants underwent a prospective comprehensive standardised assessment for a range
of AANCC (including cognitive function) through comprehensive clinical and laboratory
diagnostic means. In addition blood, urine, stool samples, as well as CSF through lumbar
puncture, were stored for biomarker analyses and several MRI modalities were used to objec-
tively assess and monitor brain structure and function. The richness of information collected
within the COBRA study would allow to improve the understanding of the pathogenic mecha-
nisms and pathways underlying HIV-related AANCC and the development of biomarkers or
biomarker combinations to assess these mechanisms. This, in turn, could result in the develop-
ment of novel prognostic tools for earlier diagnosis of AANCC and of novel interventions
Table 3. Sociodemographic, anthropometric and lifestyle characteristics of COBRA participants enrolled in the Netherlands and remaining participants enrolled
in the AGEhIV cohort study.
Variable, n (%) or median (IQR) HIV-positive HIV-negative
COBRA participants
(N = 75)
Rest of AGEhIV
(N = 523)
p COBRA participants
(N = 50)
Rest of AGEhIV
(N = 500)
p
Gender <0.01 <0.01
Female 0 (0%) 64 (13.8%) 0 (0%) 79 (16.6%)
Male 75 (100%) 401 (86.2%) 50 (100%) 397 (83.4%)
Ethnicity 0.18 0.15
Black-African 7 (9.5%) 80 (15.4%) 1 (2.0%) 38 (7.6%)
White 67 (90.5%) 439 (84.6%) 48 (98.0%) 462 (92.4%)
Sexual orientation 0.32 0.27
Gay/homosexual 63 (84.0%) 353 (77.3%) 42 (84.0%) 366 (77.4%)
Bisexual 6 (8.0%) 39 (8.5%) 4 (8.0%) 29 (6.1%)
Heterosexual 6 (8.0%) 65 (14.2%) 4 (8.0%) 78 (16.5%)
Age in years 54 (49, 61) 52 (48, 59) 0.07 55 (50, 63) 52 (47, 58) <0.01
Weight [kg] 78.8 (70.0, 85.2) 77.0 (68.6, 86.3) 0.52 81.6 (74.6, 91.8) 79.5 (71.8, 86.6) 0.07
Height [cm] 178 (175, 184) 178 (172, 184) 0.06 182 (176, 186) 179 (173, 184) 0.07
BMI [kg/m2] 24.2 (22.3, 26.1) 24.3 (22.4, 26.8) 0.44 24.6 (23.3, 27.9) 24.5 (22.8, 27.1) 0.42
Smoking status 0.13 0.52
Current smoker 24 (32.0%) 149 (32.0%) 10 (20.0%) 119 (25.0%)
Ex-smoker 33 (44.0%) 156 (33.6%) 23 (46.0%) 181 (38.0%)
Never smoked 18 (24.0%) 160 (34.4%) 17 (34.0%) 176 (37.0%)
Pack-years of smoking [current smokers] 20 (8, 35) 25 (10, 40) 0.52 4 (2, 12) 20 (8, 36) 0.01
Years of smoking [current/ex-smokers] 27 (21, 35) 31 (20, 37) 0.30 21 (13, 30) 28 (15, 35) 0.09
Alcohol consumption 0.22 0.25
Current drinker 62 (82.7%) 338 (73.5%) 46 (93.9%) 405 (85.4%)
Ex-drinker 9 (12.0%) 76 (16.5%) 1 (2.0%) 34 (7.2%)
Never drank 4 (5.3%) 46 (10.0%) 2 (4.1%) 35 (7.4%)
Years of drinking [current/ex drinkers] 35 (30, 42) 34 (29, 39) 0.27 38 (33, 47) 34 (30, 40) <0.01
Alcohol units/week [current drinkers] 5.5 (1.5, 7.5) 3.5 (1.5, 7.5) 0.19 4.5 (1.5, 9.0) 5.5 (1.5, 7.5) 0.90
Ever used injected drugs 0 (0.0%) 19 (4.2%) 0.07 0 (0.0%) 6 (1.3%) 0.43
Use of recreational drugs (past 6 months) 32 (42.7%) 119 (26.1%) <0.01 14 (28.0%) 127 (26.9%) 0.86
NB: Only numbers and proportion of people with complete information are reported for each variable
https://doi.org/10.1371/journal.pone.0191791.t003
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which, as an adjunct to cART, may prevent AANCC, thereby further reducing morbidity and
mortality and improving quality of life in people living with HIV.
The enrolment of participants at two clinical sites, Amsterdam (Netherlands) and London
(UK), enhanced recruitment rates and allowed the recruitment of a diverse group of HIV-posi-
tive individuals highly representative of the aging population of people living with HIV in care
in these countries and in other resource-rich countries in Europe and North-America. Both
centres are leading two large prospective cohort studies on co-morbidity and aging in HIV
and have established expertise in the conduct of longitudinal cohorts of HIV-positive people
and for the recruitment of comparable HIV-negative controls. The characteristics of people
enrolled in these two larger cohorts are representative of those of similarly-aged people living
with HIV commonly seen in clinics in Amsterdam and in London and comparable HIV-nega-
tive people [29, 32]. Participants enrolled into the COBRA study at each site were largely repre-
sentative of these two larger cohort studies. Although HIV-positive participants enrolled in
Table 4. Sociodemographic, anthropometric and lifestyle characteristics of COBRA participants enrolled in the UK and remaining participants enrolled in the
POPPY study.
Variable, n (%) or median (IQR) HIV-positive HIV-negative
COBRA participants
(N = 59)
Rest of POPPY
(N = 640)
p COBRA participants
(N = 29)
Rest of POPPY (N = 275) p
Gender 0.49 0.07
Female 9 (15.3%) 78 (12.2%) 6 (20.7%) 103 (37.5%)
Male 50 (84.7%) 562 (87.8%) 23 (79.3%) 172 (62.5%)
Ethnicity 0.72 0.21
Black-African 9 (15.3%) 87 (13.6%) 1 (3.5%) 30 (10.9%)
White 50 (84.7%) 553 (86.4%) 28 (96.5%) 245 (89.1%)
Sexual orientation 0.38 0.16
Gay/homosexual 41 (71.9%) 421 (77.3%) 17 (58.6%) 86 (41.6%)
Bisexual 4 (7.0%) 19 (3.5%) 0 (0.0%) 8 (3.9%)
Heterosexual 12 (21.1%) 105 (19.3%) 12 (41.4%) 113 (54.6%)
Age in years 58 (53, 63) 56 (53, 62) 0.35 60 (55, 64) 58 (53, 63) 0.12
Weight [kg] 80.0 (70.0, 88.0) 77.4 (69.8, 87.2) 0.47 77.0 (71.0, 89.0) 78.7 (69.8, 89.4) 0.81
Height [cm] 175 (168, 180) 174 (169, 179) 0.84 177 (168, 179) 172 (163, 179) 0.14
BMI [kg/m2] 25.4 (23.3, 28.7) 25.7 (23.4, 28.4) 0.76 24.9 (23.2, 30.4) 26.9 (24.2, 29.5) 0.35
Smoking status 0.33 <0.01
Current smoker 16 (27.1%) 142 (22.3%) 10 (44.8%) 32 (11.7%)
Ex-smoker 25 (42.4%) 238 (37.4%) 6 (20.7%) 115 (42.1%)
Never smoked 18 (30.5%) 257 (40.3%) 13 (44.8%) 126 (46.2%)
Pack-years of smoking [current smokers] 21 (7, 42) 20 (9, 38) 0.94 22 (2, 62) 19 (5, 41) 0.75
Years of smoking [current/ex-smokers] 31 (15, 40) 33 (20, 39) 0.80 37 (27, 45) 25 (12, 36) 0.01
Alcohol consumption 0.18 0.96
Current drinker 42 (71.2%) 513 (80.2%) 25 (86.2%) 237 (86.2%)
Ex-drinker 9 (15.2%) 79 (12.3%) 2 (6.9%) 22 (8.0%)
Never drank 8 (13.6%) 48 (7.5%) 2 (6.9%) 16 (5.8%)
Years of drinking [current/ex drinkers] 38 (34, 44) 39 (35, 45) 0.43 42 (36, 48) 41 (35, 46) 0.37
Alcohol units/week [current drinkers] 4.0 (2.0, 18.0) 8.0 (3.0, 19.0) 0.23 10.0 (4.0, 20.0) 10.0 (3.0, 18.0) 0.59
Ever used injected drugs 6 (10.2%) 56 (8.8%) 0.72 0 (0.0%) 8 (2.9%) 0.35
Use of recreational drugs (past 6 months) 12 (20.3%) 164 (25.6%) 0.37 4 (13.8%) 40 (14.6%) 0.91
NB: Only numbers and proportion of people with complete information are reported for each variable
https://doi.org/10.1371/journal.pone.0191791.t004
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Amsterdam were more likely to be successfully on cART treatment as compared to the rest of
the AGEhIV cohort, this was purposely decided by restricting the recruitment into COBRA to
individuals on cART and with suppressed HIV viral load at first study visit. However, while
these findings suggest that future results provided by the COBRA cohort could be generalised
to most aging populations of people living with HIV in care in resource-rich countries in
Europe and North-America, it is unclear whether they will be equally generalizable to other
HIV-positive populations where, among the other things, rates of cART use and viral suppres-
sion, as well as gender/ethnicity/sexual orientation profiles may differ markedly.
In summary, recruitment characteristics of this cohort study mean that it is a representative
sample of middle-aged HIV-positive people living with HIV in the Netherlands and the UK.
Its results will therefore have implications for understanding the link between HIV and
AANCC and will provide a robust estimate of the effect of treated HIV infection on the preva-
lence, incidence and age of onset of AANCC. The results will also give further insights into the
pathogenic mechanism underlying this link, including the possible induction of an inflamma-
tion-associated accelerated aging phenotype.
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